Emergent BioSolutions (EBS) Cash from Investing Activities Growth (3y) (2013 - 2026)
Emergent BioSolutions (EBS) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -53.63% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -55.36% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 34.35% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 33.61% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 15.92% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -2.45% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -36.76% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | -30.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.12% |
| Mar 31, 2026 | 45.83% |
| Dec 31, 2025 | 55.88% |
| Sep 30, 2025 | 76.78% |
| Jun 30, 2025 | 36.37% |
| Mar 31, 2025 | 56.70% |
| Dec 31, 2024 | 37.94% |
| Sep 30, 2024 | 59.12% |
| Jun 30, 2024 | 59.05% |
| Mar 31, 2024 | 42.26% |
| Dec 31, 2023 | 32.40% |
| Sep 30, 2023 | 25.50% |
| Jun 30, 2023 | 97.59% |
| Mar 31, 2023 | 14.55% |
| Dec 31, 2022 | -7.94% |
| Sep 30, 2022 | -160.86% |
| Jun 30, 2022 | -10.03% |
| Mar 31, 2022 | -14.59% |
| Dec 31, 2021 | 62.21% |
| Sep 30, 2021 | -28.36% |